The industry’s focus is on living organisms, and the highly controlled standards make it a distinct consideration for business leaders. These aspects make the sector an ideal place to foster innovation. They have resulted in major breakthroughs in the production of biofuels and agricultural yields and life-saving pharmaceuticals.
When you think of strategies to generate revenue biotech start-ups have a myriad Click Here of options. The majority of them choose a technology partnership or an asset creation-and-out licensing strategy. Technology partnering can bring faster revenue and lower financial risk, while outlicensing and asset creation strategies are able to yield much more returns. A growing number of biotechs in the early stages of research employ a hybrid strategy that combines these two approaches.
If you choose to go with an approach to development that is oriented towards product will succeed commercially when they get their pipeline to a suitable stage and find a pharmaceutical partner or investor with a large sum of money. This is costly, however, and the balance of opportunistic strategies to leverage outside assets with the right scientific decisions about homegrown projects is key.
The “platform” model is another alternative to generate revenue. It is less costly than product-oriented development but also comes with a high risk. In this model, biotechs own and develop their own platform technology prior to teaming with pharma giants to create a portfolio of drug discovery initiatives that target specific diseases (i.e. disease of x in biology). Advinus Therapeutics, among others, have adopted this approach.